lovastatin has been researched along with Genetic Predisposition in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Giacomo, S; Mazza, F; Mesce, D; Morozzi, C; Pergolini, M; Stefanutti, C; Vitale, M | 1 |
| Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A | 1 |
| Al-Jazrawe, M; Alman, BA; Pathmanapan, S; Poon, R; Puviindran, V; Ramu, E; Tang, YJ; Tsushima, H; Wei, Q; Wunder, J; Zhang, H | 1 |
| Alli, E; Fernandez, AM; Ford, JM; Jensen, K; Kardashian, A; Kurian, AW; Lipson, J; McPherson, L; Mills, MA; Schackmann, EA; Schwartz, EJ; Sharma, VB; Staton, A; Telli, ML; Vinayak, S | 1 |
| Averna, M; Blom, D; Cefalù, AB; Ciccarese, M; Cossu, M; Croyal, M; Dallinga-Thie, G; Guédon, A; Hovingh, K; Lambert, G; Passard, M; Peter, J; Pintus, P; Pisciotta, L; Prampart-Fauvet, S; Raal, F; Santos, RD; Sjouke, B; Thedrez, A | 1 |
| Chatterjee, VK; Chen, CS; Eng, C; Shaiu, CW; Teresi, RE; Waite, KA | 1 |
| Brown, BG; Brunzell, JD; Hokanson, JE; Motulsky, AG; Zambon, A | 1 |
| Stankler, L | 1 |
3 trial(s) available for lovastatin and Genetic Predisposition
| Article | Year |
|---|---|
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticarcinogenic Agents; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Density; Breast Neoplasms; C-Reactive Protein; Deoxyguanosine; DNA Damage; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Lipid Peroxidation; Lipids; Lovastatin; Mammary Glands, Human; Middle Aged; Oxidative Stress; Patient Compliance | 2013 |
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Dyslipidemias; Genetic Predisposition to Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin; Pharmacogenetics; Treatment Outcome | 2006 |
5 other study(ies) available for lovastatin and Genetic Predisposition
| Article | Year |
|---|---|
Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
Topics: Adult; Aged; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Diet, Fat-Restricted; Dietary Supplements; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Monascus; Mutation; Phenotype; Time Factors; Treatment Outcome; Young Adult | 2017 |
Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
Topics: Animals; Cell Survival; Cholesterol; Chondrocytes; Chondroma; Chondrosarcoma; Disease Models, Animal; Genetic Predisposition to Disease; Isocitrate Dehydrogenase; Lovastatin; Mice; Mice, Knockout; Xenograft Model Antitumor Assays | 2019 |
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type III; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Proprotein Convertase 9; Receptors, LDL; Serine Proteinase Inhibitors; Young Adult | 2016 |
Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; G1 Phase; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Hypoglycemic Agents; Lovastatin; PPAR gamma; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Up-Regulation | 2006 |
Goals for cholesterol lowering.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Genetic Predisposition to Disease; Goals; Humans; Lovastatin; Reference Values | 1999 |